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Renal function 17 to 23 years after chelation therapy for childhood
plumbism. An elegant retrospective description of an epidemic of
chronic renal failure occurring in patients with histories of untreated
childhood lead poisoning in Queensland, Australia established beyond
reasonable doubt the existence of lead nephropathy. However, a
retrospective uncontrolled report from Boston in 1963 refuted the claim
that there are serious renal consequences of untreated childhood lead
poisoning. We conducted a controlled prospective, longitudinal study
to examine the effects of childhood lead poisoning on renal function 17
to 23 years after chelation therapy. The present study reports the results
of renal functional tests in a unique cohort of study subjects (N = 62)
with significant lead poisoning (initial PbB > 100 g/dl) diagnosed and
treated between 1966 and 1972 and their age-matched control siblings(N = 19; initial PbB < 40 g/dl). During the past nine years serial
determinations of renal function on all study subjects and control
siblings were obtained. Mean values of systolic and diastolic blood
pressures, serum creatinine, serum 132-microglobulin, fractional excre-
tion /32-microglobulin, urinary protein:creatinine ratio, serum phos-
phate, tubular reabsorption of phosphate, serum uric acid, and urinary
specific gravity were similar in study subjects compared with sibling
controls. The frequency of abnormal values for these tests was similar
in the two groups. Multiple linear regression analyses failed to demon-
strate a significant influence of the presence of plumbism or initial PbB
on serum creatinine or systolic or diastolic blood pressure. A modest
increase in serum creatinine values was observed over a nine year
period in four of 62 study subjects (1.4, 1.4, 1.5, 1.6 mg/dl). There were
no statistical differences in either renal function or blood pressure
between study subjects and control siblings. The possibility exists that
longer follow-up is necessary to determine whether these subjects are at
risk of developing lead nephropathy. The four of 62 patients identified
with modestly elevated serum creatinine values will require close
long-term follow-up.
A careful retrospective analysis, published in 1955, of a
remarkable prevalence of childhood lead poisoning in Queens-
land, Australia and the attendant renal sequelae established the
existence of lead nephropathy [1]. The observers described an
unusually high incidence of deaths from renal disease among
untreated adolescents and adults with early histories of lead
poisoning or heavy exposure to lead-based paint. In a series of
articles, the characteristic clinical presentation with contracted
kidneys, hypertension, benign urinary sediment, renal failure
and in half the cases gout, was defined; the association with
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elevated skeletal lead and EDTA mobilized lead was estab-
lished [1—4]. Another retrospective study in 1963 from Boston
cast doubt on the claim of serious renal consequences following
untreated childhood plumbism [5]. This study of 42 subjects has
been rightly criticized because it lacked an age-matched control
group and presentation of raw data.
In 1983 we performed renal functional tests in 74 subjects
(initial PbB  100 p.g/dl) who were treated for lead poisoning
between 1966 and 1972 and 21 sibling controls (initial PbB <40
jgIdl) [6]. We found few if any renal functional abnormalities 9
to 17 years after childhood lead poisoning. The present longi-
tudinal study with age-matched control siblings represents a
re-evaluation of 62 of the original 74 subjects, 17 to 23 years
after treatment for childhood lead poisoning.
Methods
Study population and control group
In October 1966, the Chicago Board of Health initiated an
intensive case-finding program to detect incipient lead poison-
ing in young children in high-incidence neighborhoods. Patients
were identified by a screening program using venous blood lead
(PbB) determinations. When a subject was identified with PbB
greater than 40 g/dl the subject's siblings were screened. A
specialized clinic was opened in 1967 for evaluation and treat-
ment of children with PbB greater than or equal to 40 g/dl.
Confirmation was made by a second PbB determination and by
radiographs of the abdomen, wrist, and knee. Chelating agents
were CaNa2-EDTA alone or in combination with BAL, fol-
lowed by peniciHamine orally.
The patients attended the Lead Clinic for periods of several
months to five years and were discharged after PbB remained
<50 tg/dl for two consecutive months. Lengthy observation in
many instances was necessitated by a slow drop in PbB [7].
A longitudinal study to evaluate sequelae begin in 1974,
enrolling 215 study patients with initial PbB greater than or
equal to 50 g/dl and 47 control siblings with initial PbB less
than 40 j.g/dl. Over the next fifteen years, patients were recalled
a mean of 5.6 times for elevation. During these years of
observation, three study subjects experienced violent deaths
involving handguns (2) and bludgeoning. The focus of each
recall was assessment of physical and neurological status and of
intellectual function [8]. Because of the paucity of abnormalities
discovered during early evaluation of the entire group, empha-
sis in the past three recalls was placed on study subjects with
initial PbB greater or equal to 100 p.gldl. In the present study 62
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study subjects, PbB  100 g/dl and 19 control siblings, PbB <
40 gIdl, were evaluated. During the case-finding program in
the late 1960's PbB's below 40 ig/dl were not further quantified.
Eighteen of 19 control and 59 of 62 study subjects were
African-American. All subjects but one in the study cohort had
been treated and examined during each recall by one of us
(H.K.S.).
Study protocol
Each subject and sibling control was contacted and given an
appointment for the renal clinic. After an informed consent
form was signed, an interval history was obtained and physical
examination performed including height, weight, and blood
pressure. Body mass index was calculated by dividing weight
by the square of the height. Urinalysis was performed on a fresh
urine sample by an attending nephrologist. A venous blood
sample was obtained for tests of renal function (see below) and
for PbB and zinc protoporphyrin (ZPP) (determined at the lead
laboratory of the Chicago Board of Health by atomic absorption
spectroscopy and hematofluorometry).
Bloodpressure
All blood pressures were measured by one physician
(H.K.S.) with a 13 cm wide cuff and mercury-gravity manom-
eter on the subject's right arm, while in the sitting position for
10 minutes, taking the fourth Korotkoff phase (muffled) as the
diastolic pressure. Systolic blood pressures 140 mm Hg and
diastolic 90 mm Hg were considered abnormal [9].
Urinalysis
Urinary pH, protein, and glucose were determined with
Labstix (Ames Co. Elkhart, Indiana, USA). Specific gravity
was measured by refractometry. A microscopic examination of
the sediment was performed on a spun sample.
Renal function tests
Serum creatinine was determined by a modification of the
Jaffé method on an automatic analyzer. Values greater than 1.3
mg/dl (2 SD above the mean of sibling control values) were
considered abnormal.
An aliquot of urine was used for determination of total
protein and creatinine. Total protein was determined by spec-
trophotometry using a modification of the biuret reaction.
Urinary protein/urinary creatinine (mg/mg) greater than 0.16
(2 SD above the mean of sibling control values) was considered
abnormal.
Serum 132-microglobin (132m) levels in serum and urine were
determined by radioimmunoassay (Phadebas f32-MicroTest;
Pharmacia Diagnostics, Uppsala, Sweden). Serum values
greater than 1.27 mg/liters (2 SD above the mean of sibling
control values) were considered abnormal.
Fractional excretion /32m (FEpm%) x 100 was calculated as
100(1 — Up2m/Pp2m\ Ur/P
where U is urinary concentration and P is plasma concentra-
tion. Values of FE,m x 100 greater than 13 (2 SD above the
mean of sibling control values) were considered abnormal.
Table 1. Selected clinical data in subjects with lead poisoning
(maximum PbB > 100 sgIdl) and sibling controls (PbB < 40 /dl)
Study subjects(N=62) Sibling controls(N= 19) P
Present age years 22.2 2.3 22.3 3.8 NS
Sex(M:F) 25:37 5:14
Age at diagnosis year 2.2 0.4
Initial PbB /2g/dl 150.3 77.1
1983 PbB pg/dl 14.5 4.5 11.6 2.6 <0.01
1989 PbB g/dl 7.4 0.1 7.4 2.6 NS
1989 ZPP pg/dl 19.0 11.9 17.0 12.4 NS
1989 Hct % 39.5 6.4 38.1 4.6 NS
Weight kg 77.2 21.3 62.3 16.8 <0.025
Height cm 168.0 10.4 167.1 9.7 NS
Body mass index kg/rn2 27.2 6.8 22.2 4.0 <0.025
NS, not significant.
Serum phosphate was determined by a spectrophotometric
method on an automatic analyzer. Values greater than 5.6 mg/dl
(2 SD above the mean of sibling control values) were considered
abnormal. Tubular reabsorption phosphate (TRP) was calcu-
lated after determining the concentration of phosphate and
creatinine simultaneously in blood and urine. TRP was calcu-
lated as
/Up04 X PCr\
I Ixl00Ur x
where U is urinary concentration and P is plasma concentration
in mg per deciliter. Values of TRP less than 85% (2 SD below the
mean of sibling control values) were considered abnormal.
Serum uric acid was determined by a spectrophotometric
method on an automatic analyzer. Values greater than 7.02
mg/dl (2 SD above the mean sibling control values) were
considered abnormal.
Statistical methods
Statistical methods used included the Student's t-test for
unpaired means and chi-square analysis for comparison of
incidence of abnormal values between study subjects and
control siblings. We calculated 95% and 99% confidence inter-
vals for mean serum creatinine from the literature [10, 11], and
contrasted them with the mean values from our study. Further,
multiple linear regression analyses were performed with a
general formula: ' = & + X X1 + f3 x X2 . . ., where 's
were serum creatinine, systolic and diastolic blood pressures
and X1, X2 . . . etc., were age, body mass index, gender and
exposure to lead. Because the PbBs were reported only as 40
g/dl in the controls, we carried out two separate analyses: in
one we considered 40 tg/dl as the lead level in the controls and
in the other lead exposure was included as a dichotomous
variable in the equation. Results are expressed as mean 1 SD.
Results
Selected clinical data
Mean ages in the study subject and sibling control groups
were similar (Table 1). The study subject mean age was 22.2
2.3 years and the interval since diagnosis was 20.0 1.9 years.
The male:female ratio in the study subjects was approximately
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Table 2. Blood pressure in 62 subjects and 19 sibling controls
Study subjects Sibling controls
Abnormal Abnormal
Mean results Mean results
lsD N % lsD N %
Blood pressure
mm Hg
Systolic 118.1 12.8 6 10 116.3 16.8 I 5
Diastolic 78.7 10.5 II 18 78.9 14.2 I 5
Table 3. Final regression model for systolic blood pressure
Variable 3 coefficient SE P value
N = 81; R2 = 0.3l9
Age year —0.0678 0.5521 0.9026
Sex (Male = 1; female = 0) 7.0479 2.8448 0.0158
Initial PbB jsg/dl —0.0153 0.0172 0.3772
Body mass index kg/rn2 1.0107 0.2034 <0.0001
N = 81; R2 = 0.324
Age —0.0715 0.54986 0.8969
Plumbism (yes = I; no = 0) —4.7048 4.1372 0.2596
Sex 6.7802 2.7529 0.0164
Body mass index 1.0771 0.2096 <0.0001
2:3 compared to 1:3 in the sibling controls. The mean initial PbB
level before chelation therapy in the study subjects was 150
77.1 sgIdl, range 100 to 471 gIdl. There was a small but
significant difference in 1983 PbBs between study subjects
compared to control subjects (14.5 4.5 gIdl vs. 11.6 2.6
g/dl); this reconfirms that overall lead exposure was greater in
study subjects compared to sibling controls. However, in 1989,
PbBs in both groups were similar. Hematocrit and ZPP's in
1989 were also similar. There was a significant difference in
weight between the two groups with study subjects weighing
more than sibling controls (77.2 21.3 kg vs. 62.3 16.8 kg).
Similarly, body mass index was greater in study subjects
compared to sibling controls (27.2 6.8 vs. 22.2 4.0). Height
in the two groups was similar.
Blood pressure
There was no significant difference in either systolic or
diastolic blood pressures in the study subjects compared to
sibling controls; twelve study subjects demonstrated either
elevated systolic or diastolic blood pressure (Table 2). How-
ever, six of 12 hypertensive study subjects weighed more than
100 kg. There was no difference in the incidence of elevated
blood pressure between the two groups by chi-square analysis.
The results of multiple linear regression analyses (Tables 3 and
4) revealed that systolic and diastolic blood pressures to be
positively correlated with body mass index (f3 of 1.1 mm Hg
increase in systolic blood pressure and 0.6 mm Hg increase in
diastolic blood pressure per unit of body mass index, P <
0.0001 and <0.0009, respectively) and moderately correlated
with gender (13 of 6.8 mm Hg systolic blood pressure increase in
males, P <0.02). Neither exposure to lead (dichotomous entry
in the model) nor initial PbB level had any significant effect on
blood pressure, when gender, age, and body mass index were
controlled.
Table 4. Final regression model for diastolic blood pressure
Variable f3 coefficient SE P value
N = 81; R2 = 0.179
Age year —0.0257 0.4794 0.9573
Sex (Male = I; female = 0) 4.1628 2.4703 0.0968
Initial PbB pg/dl 0.0020 0.0149 0.8903
Body mass index kg/rn2 0.5785 0.1767 0.0017
N = 81; R2 = 0.188
Age —0.0557 0.4746 0.9069
Sex 4.6172 2.3761 0.0563
Plumbism (yes = I; no = 0) —4.0879 3.5710 0.2565
Body mass index 0.6310 0.1809 0.0009
Urinalysis
The mean urinary specific gravity was similar in the two
groups (Table 5). Despite not requesting a first-voided urine
specimen after an overnight fast, only four study subjects and
two control siblings failed to concentrate urine greater than
specific gravity 1.020. Microscopic hematuria (>5 RBC per
high-power field) on a spun sample was observed in three
female study subjects who were menstruating at the time of the
examination; the urinalyses were not subsequently repeated.
Four study subjects showed 30 mg/dl protein by Labstix but
none had urinary protein/creatinine (Uprøt/Ur) >0.16.
Renal function tests
Mean serum creatinine concentration was similar in sibling
controls and in study subjects. However, four male study
subjects had serum creatinine levels greater than 1.3 mg/dl (1.6,
1.5, 1.4, 1.4 mg/dl). These four subjects are discussed in detail
below. Chi-square analysis failed to reveal a significant differ-
ence in the incidence of abnormal serum creatinine values
between the two groups.
Mean serum 132m values were similar in each group. Eight
(12%) study subjects and 0 control subjects had serum J32m
levels greater 1.27 mg/liter; these differences in incidence were
not significant. FEp,m % x 100 were similar in the two groups.
One (5%) control subject and 2 (3%) study subjects had values
greater than 13.
Mean Upr0t/U values were similar in the two groups and
there were no significant differences in the number of abnormal
values in each group. Mean serum phosphorus values were
similar in each group as were the mean values of TRP. Simi-
larly, there were no differences in mean values of serum uric
acid levels between the two groups.
Exposure to lead or initial PbB did not significantly influence
any of the renal function variables tested: serum creatinine
(Table 6), serum /32m, FEP,m% X 100, Uprot/Ucr, serum phos-
phorus, TRP, serum uric acid, and urine specific gravity. Age
and male gender significantly influenced serum creatinine (Ta-
ble 6) and uric acid levels. Body mass index influenced serum
uric acid, but its effect on serum creatinine did not reach
significance.
Elevated serum creatinine
Of the four study subjects with elevated 1989 serum creati-
nine values, three demonstrated slightly elevated values in 1980
and 1983. Blood pressure and other renal functional tests were
normal in these four study subjects. In all four study patients a
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Table 5. Renal function tests in 62 subjects and 19 controls
Renal function tests
Study subjects Sibling controls
Mean I SD
Abnormal results
Mean I SD
Abnormal
N
results
%N %
Serum creatinine mg/dl 0.87 0.26 4 6 0.80 0.25 0 0
Serum f32m mg/liter 1.18 0.27 8 12 1.06 0.11 0 0
FEp,m % >< 100
Uprot/Ucr mg/mg
Serum phosphorus mg/dl
4.80 0.60
0.05 0.16
4.5 1.3
2
1
3
3
2
5
3.20 0.50
0.04 0.06
4.5 0.6
1
0
0
5
0
0
Tubular reabsorption of
phosphorus % 93.9 4.0 1 2 95.1 4.7 0 0
Serum uric acid ing/dI 5.0 1.3 2 3 4.4 1.3 1 5
Urine specific gravity 1.026 0.006 1.025 0.007
modest increase in serum creatinine value was noted between
1980 and 1989 (Table 7). These values were confirmed on a
second occasion. No other causes of decreased renal function
could be identified.
Discussion
The first description of chronic nephropathy following un-
treated childhood lead poisoning was that of Nye [12] in 1928
from Queensland, Australia. A careful analysis published in
1955 [1] of a remarkable epidemic of childhood lead poisoning in
Queensland and the attendant renal sequelae established be-
yond reasonable doubt the existence of lead nephropathy.
Victorian houses in Queensland characteristically had closed
verandas, painted with lead-based paint. Such verandas were
ideal for confining small children while their mothers were busy
in the house. From daily rain showers in this subtropical region,
rain droplets hung on the railings and tasted sweet from
dissolved lead. They were within the reach of toddlers, who
enjoyed wiping up and licking the rain droplets. In a remarkable
series of articles, the characteristic clinical presentation with
contracted kidneys, hypertension, benign urinary sediment,
renal failure and in half the cases, gout, was defined [1-4, 12].
Emmerson [2] in 1963 found that lead excretion following
EDTA infusion was consistently elevated only in these patients
with chronic renal disease who also had a history of previous
lead poisoning. In these studies, chronic lead nephropathy was
defined as chronic renal insufficiency with evidence of past
untreated lead absorption and storage, as shown by either a
significantly increased lead content of the skull bone at autopsy
or a significant increase in the urinary excretion of lead after a
standardized infusion of calcium EDTA. The pathologic find-
ings of chronic ncphropathy following lead poisoning in Queens-
Date of
Birth
Initial PbB
isg/dl
Serum creatinine mg/dl
1980 1983 1989
1. 07-29-66 188 1.2 1.4 1.6
2. 03-07-63 104 1.2 1.2 1.5
3. 11-13-63 328 1.2 1.4 1.4
4. 10-14-66 135 0.8 1.0 1.4
land children were described in detail by Inglis, Henderson and
Emmerson [4].
Tepper [5], by contrast, reporting on his experience in Boston
found only one patient with chronic nephropathy in 42 patients
studied 20 years after untreated childhood lead intoxication. To
explain the differences between the American and Australian
data, Tepper and other investigators noted that the age at which
lead poisoning occurred in the Queensland subjects and their
period of exposure were unknown. In Tepper's retrospective
study, lead poisoning was diagnosed either by blood lead levels
or by bone radiographic findings in only a few of the patients.
This factor lead Chisolm [13] to conclude that lead absorption in
the Queensland cases was more prolonged and that lead absorp-
tion in patients in the United States was more acute. The
Boston study [5] of 42 subjects has been widely quoted as
disproving any serious renal consequences of childhood plum-
bism. However, this study has been rightly criticized because it
lacked an age-matched control group, presentation of raw data,
and adequate diagnostic criteria of lead poisoning. Further-
more, the small size of the study group and exclusion of
subjects with low creatinine excretion render the conclusions
doubtful.
Our previous study [61 conducted in 1983, 9 to 17 years after
chelation therapy for childhood lead poisoning, failed to dem-
onstrate a significant incidence of urinary or renal functional
abnormalities. A limitation of that study was that lead poisoning
in childhood might lead to chronic nephropathy later in life; that
is, the duration of the "latency period" is unknown.
Recently, a retrospective 50-year follow-up of 22 untreated
patients from the Boston area [14] with childhood plumbism
demonstrated a significant increased risk of systolic hyperten-
sion compared to 22 matched control subjects. One study
subject died at age 40 years of interstitial nephritis. Creatinine
clearance in study subjects was elevated compared to matched
Table 6. Final regression model for serum creatinine
______—_Variable — 13 coefficient SE P value
N = 81; R2 = 0.530
Age year
Sex (Male = 1; female = 0)
lnitial PbB g/dl
Body mass index kg/m2
N = 81; R2 = 0.530
0.0 192
0.3777
—0.0000
0.0060
Table 7. Serial serum creatinine values in 4 subjects with 1989 value
> mean + 2 Sn (1.3 mg/dl)
0.0089
0.0463
0.0002
0.0033
0.0357
<0.0001
0,8132
0.07 14
Age 0.0192 0.0089 0.0358
Plumbism (yes = I; no = 0) —0.0207 0.0676 0.7597
Sex 0.3766 0.0449 <0.0001
Body mass index_— 0.0063 0.0034 0.0677
1230 Moe! and Sachs: Rena/function and childhood lead poisoning
Table 8. Normative serum creatinine values (mg/dl) during 19 to 26
years [10, 11]
N [ret] Mean SD 95% CI 99% CI
All Blacks 194 [11] 1.07 0.17 1.04, 1.09 1.04, 1.10
Black males 82
98
[11]
[10]
1.16
1.16
0.17
0.16
1.12, 1.20
1.13, 1.19
1.11, 1.21
1.12, 1.20
Black females 112
162
[11]
[10]
1.00
0.87
0.10
0.15
0.98, 1.02
0.85, 0.89
0.98, 1.02
0.84, 0.90
controls and predicted values for comparable sex and age. This
finding could suggest an intermediate state of hyperfiltration
before the onset of eventual chronic renal insufficiency. Thus,
the "latency period", greater than 50 years, may be very long.
The present study was conducted to determine whether
treated subjects are at risk of developing nephropathy 20 or
more years after childhood lead poisoning. Follow-up reevalu-
ation, conducted 17 to 23 years after chelation therapy for
childhood lead poisoning, failed to demonstrate compelling
evidence of significant incidence of urinary or renal functional
abnormalities or elevated blood pressure. It may be argued that
although sibling controls had less exposure to lead (PbB < 40
p.gIdl), this population had blood lead levels that are well above
what the Centers for Disease Control (Atlanta, Georgia, USA)
considers harmful (PbB > 10 sgIdl) [15]. Thus, the lack of
differences in blood pressure and renal function between the
two populations could be attributed to unacceptable lead expo-
sure in both groups. However, if the blood lead concentration
after chelation therapy was a significant predictor of renal
insufficiency, there should be a dose-response relationship
which we could not detect from multiple linear regression
analysis. It may be that studying a larger control group or even
an expanded one that would include a cohort of inner city
African-Americans at an equivalent age would reveal more
definitive data about the risks.
Four male study subjects were identified with serum creati-
nine values greater than 1.3 mg/dl (2 SD above the mean sibling
control value). Because the number of control siblings was
small [19], there might be a valid argument against using this
group to define the range of normal. Table 8 depicts normative
serum creatinine data from two studies of Black subjects aged
19 to 26 years. The reported mean creatinine values for Black
males was 1.16 mgldl [10, 11]. The 95% Cl's were 1.13 to 1.19
mg/dl as reported by [101 and 1.12 to 1.20 mg/dl [11]; the 99%
Cl's were 1.12 to 1.20 mg/dl [10] and 1.11 to 1.21 mg/dl [11]. The
mean values in our study for both study subjects and sibling
controls were lower than the lower limits of 99% confidence
interval reported for all Black groups reported of comparable
age. Further, only one subject had a serum creatinine of 1.6
mgldl, a value greater than the mean + 2 SD value for Black
males (1.5 mg/dl). We conclude that study subjects represent a
relatively low risk of renal insufficiency.
Although serum creatinine is a standard measurement of
renal function, it is a relatively insensitive test. In the present
study not only were levels of serum creatinine measured, but
other very sensitive indicators of renal function were deter-
mined. No differences in maximal urinary concentrating ability
or fractional excretion of /32m were revealed between study
subjects and control siblings. Furthermore, there was no rela-
tionship between these measures of renal function and initial
PbB. We could not apply a calculated creatinine clearance
based on weight and age, the Cockroft-Gault equation [15],
because of the interesting observation that study subjects
weighed more than sibling controls (77.2 vs. 62.3 kg). Pica
during childhood may represent a predictor for obesity later in
life. The modest increase in serum creatinine values observed in
the four study subjects over a nine year period in the absence of
any other evidence of renal dysfunction would suggest that
elevated creatinine values correlated with weight (62, 86.3, 97.5
and 110 kg) and the total creatinine pool rather than renal
dysfunction.
The present study failed to demonstrate significant evidence
of adverse renal or blood pressure sequelae 17 to 23 years after
treatment for childhood plumbism; this supports the concept
that chelation therapy may prevent later development of renal
sequelae. Although there were no statistical differences in
either renal function or blood pressure between study subjects
and control siblings, the possibility exists that a much larger
cohort of subjects and controls could demonstrate evidence of
renal disease in the study group. Longer follow-up may also be
necessary to determine whether study subjects are at risk of
developing nephropathy 25 or more years after childhood lead
poisoning.
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